Header Logo

Connection

RAMMURTI KAMBLE to Transplantation, Homologous

Back to Details
This is a "connection" page, showing publications RAMMURTI KAMBLE has written about Transplantation, Homologous.
RAMMURTI KAMBLE
Connection Strength
2.429
Transplantation, Homologous
  1. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):506-10.
    View in: PubMed
    Score: 0.226
  2. Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2006 Apr; 57(4):795-6.
    View in: PubMed
    Score: 0.223
  3. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer. 2021 02 15; 127(4):609-618.
    View in: PubMed
    Score: 0.154
  4. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct; 21(5):e13145.
    View in: PubMed
    Score: 0.141
  5. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2014 Feb; 20(2):202-8.
    View in: PubMed
    Score: 0.095
  6. Cerebrospinal leukemoid reaction secondary to VZV meninigoencephalitis in an AML patient post allogeneic bone marrow transplantation. Blood. 2013 Jul 11; 122(2):300-1.
    View in: PubMed
    Score: 0.093
  7. Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles. Bone Marrow Transplant. 2012 Oct; 47(10):1370-1.
    View in: PubMed
    Score: 0.084
  8. Acute gout at engraftment following hematopoietic transplantation. Am J Hematol. 2011 Nov; 86(11):961-2.
    View in: PubMed
    Score: 0.082
  9. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011 Aug 18; 118(7):1979-88.
    View in: PubMed
    Score: 0.081
  10. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6.
    View in: PubMed
    Score: 0.061
  11. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
    View in: PubMed
    Score: 0.060
  12. Leukemia burden and outcome of allogeneic transplant in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2006 Jun; 12(6):691-2.
    View in: PubMed
    Score: 0.057
  13. Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 Dec; 30(12):1193.e1-1193.e8.
    View in: PubMed
    Score: 0.050
  14. Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study. Lancet Child Adolesc Health. 2024 10; 8(10):740-750.
    View in: PubMed
    Score: 0.050
  15. Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant. 2024 02; 59(2):196-202.
    View in: PubMed
    Score: 0.048
  16. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
    View in: PubMed
    Score: 0.043
  17. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022 04; 28(4):187.e1-187.e10.
    View in: PubMed
    Score: 0.042
  18. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021 10 20; 39(30):3328-3339.
    View in: PubMed
    Score: 0.040
  19. Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplant Cell Ther. 2021 09; 27(9):785.e1-785.e6.
    View in: PubMed
    Score: 0.040
  20. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood. 2021 01 28; 137(4):556-568.
    View in: PubMed
    Score: 0.039
  21. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. Blood Adv. 2020 10 13; 4(19):4748-4757.
    View in: PubMed
    Score: 0.038
  22. Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. Biol Blood Marrow Transplant. 2020 08; 26(8):1446-1451.
    View in: PubMed
    Score: 0.037
  23. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020 05 12; 4(9):2084-2094.
    View in: PubMed
    Score: 0.037
  24. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2020 03; 26(3):553-561.
    View in: PubMed
    Score: 0.036
  25. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019 10 22; 3(20):3123-3131.
    View in: PubMed
    Score: 0.036
  26. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2020 05; 105(5):1329-1338.
    View in: PubMed
    Score: 0.036
  27. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 05; 54(5):648-661.
    View in: PubMed
    Score: 0.034
  28. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica. 2017 11; 102(11):1823-1832.
    View in: PubMed
    Score: 0.031
  29. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica. 2017 05; 102(5):958-966.
    View in: PubMed
    Score: 0.030
  30. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer. 2017 05 15; 123(10):1828-1838.
    View in: PubMed
    Score: 0.030
  31. Allogeneic Transplantation for Relapsed Waldenstr?m Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Transplant. 2017 01; 23(1):60-66.
    View in: PubMed
    Score: 0.029
  32. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transplant. 2016 08; 22(8):1493-1503.
    View in: PubMed
    Score: 0.028
  33. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol. 2016 06 01; 34(16):1864-71.
    View in: PubMed
    Score: 0.028
  34. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016 07; 174(2):235-48.
    View in: PubMed
    Score: 0.028
  35. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biol Blood Marrow Transplant. 2016 06; 22(6):1056-1064.
    View in: PubMed
    Score: 0.028
  36. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015 Jan; 21(1):151-8.
    View in: PubMed
    Score: 0.025
  37. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1777-84.
    View in: PubMed
    Score: 0.025
  38. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant. 2014 Apr; 20(4):587-92.
    View in: PubMed
    Score: 0.024
  39. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97.
    View in: PubMed
    Score: 0.024
  40. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70.
    View in: PubMed
    Score: 0.024
  41. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.024
  42. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013 May; 19(5):746-53.
    View in: PubMed
    Score: 0.023
  43. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013 Apr; 19(4):625-31.
    View in: PubMed
    Score: 0.022
  44. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1776-84.
    View in: PubMed
    Score: 0.022
  45. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant. 2012 Jun; 47(6):831-7.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.